As Apple gradually shits its Mac devices to its own Silicon M1 chip, the purpose of the first generation of Apple Silicon is aimed at creating a new experience, to achieve the balance of performance and power consumption, instead of high computing.
On November 10, Apple introduced three new Mac devices — MacBook Air, MacBook Pro and Mac Mini — powered by the Apple M1 system on a chip (SoC).
“While the inability of Intel chips to meet emerging requirements was the apparent trigger for Apple to have own chips, there were many other benefits and possibilities pushing the move,” according to Brady Wang, a senior research analysts with Counterpoint Research.
Just like iOS and Android, Apple’s macOS has a different ecosystem than Windows.
“The slow improvement in PC hardware, which is dominated by Intel, is among the key factors affecting macOS’ progress,” Wang wrote in a blog post.
The M1 specifications are similar to those of the A14 Bionic. However, the M1 on a Mac device can deliver more computing power and applications than the A14 Bionic on an iPhone.
Both are manufactured at TSMC’s 5nm and feature custom high-performance (Firestorm), energy-efficient (Icestorm), GPU and NPU.
However, the M1 has two more high-performance cores than the A14 Bionic, as well as additional cache and peripheral circuitry.
According to Apple, the M1 has 16 billion transistors, about 35 per cent more than the A14 Bionic.
Depending on the applications’ environment, power consumption, thermal efficiency and footprint are essential considerations in designing SoCs.
“Thanks to the advantages of the advanced process in TSMC in terms of power consumption and transistor density, the M1 performs better on Mac devices than on previous Intel-based MacBook,” Wang argued.
Unlike Intel CPUs that emphasise a maximum clock rate, the Apple M1 clock rate is dynamic.
The M1 utilises energy-efficient cores to achieve lower system power consumption and multitasking workload.
However, in addition to the limitations inherited from the Apple AX SOC, the M1’s maximum clock rate cannot boost to 4.8GHz like Intel’s latest Tiger Lake CPU (10nm), which is more likely due to TSMC’s process limitations.
According to Wang, unlike the legacy architecture in traditional PCs, the M1 embeds high-bandwidth and low-latency memory DRAM into a single pool within a custom package.
“Therefore, all cores can retrieve data in the memory simultaneously, and the system can dynamically arrange the precious memory resource. This dramatically improves system performance and reduces the usage of power-hungry DRAM, consequently extending the battery life”.
The next generation of Apple chips will have more high-performance cores to meet the requirements of multitasking and high-performance PC applications.
“Counterpoint believes Apple Silicon will integrate AP and GPU into a single chip by using advanced package,” Wang said.
From today India to export COVID-19 vaccines to these countries.
The Ministry of External Affairs said India will supply COVID-19 vaccines to partner countries over the coming weeks and months in a phased manner keeping in view the domestic requirements.
India, one of the world’s leading drug makers, will start exporting vaccines for the novel coronavirus from today. The country will provide supplies of Covid-19 vaccines to Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles under grant assistance. Shipments will be sent to Sri Lanka, Afghanistan and Mauritius as well on receipt of necessary regulatory clearances.
In a tweet, Prime Minister Narendra Modi said India is deeply honored to be a “long-trusted” partner in meeting the healthcare needs of the global community and that supplies of the vaccines to several countries will commence on Wednesday, and more will follow in the days ahead.
“In response to these requests, and in keeping with India’s stated commitment to using India’s vaccine production and delivery capacity to help all of the humanity fight the COVID pandemic, supplies under grant assistance to Bhutan, Maldives, Bangladesh, Nepal, Myanmar and Seychelles will begin from January 20,” it said.
The Bangladesh foreign ministry said it expected to receive a gift of two million doses on Thursday. The country of 160 million, which has yet to start its vaccination programme, has ordered a further 30 million doses, officials said.
The Oxford/AstraZeneca vaccine is widely viewed as their best option because the other two, manufactured by Pfizer/BioNTech and by Moderna, need to be stored at very low temperatures. WHO emergency authorization for the Astra-Oxford vaccine would additionally allow SII to begin supplying it to the WHO-backed COVAX initiative aimed at fairly distributing COVID-19 shots across the world.
India has already rolled out a massive coronavirus vaccination drive under which two vaccines, Covishield and Covaxin, are being administered to frontline health workers across the country. While Oxford-AstraZeneca’s Covishield is being manufactured by the Serum Institute, Covaxin is being produced by Bharat Biotech.
“In an ongoing effort, India will continue to supply countries all over the world with vaccines. This will be calibrated against domestic requirements and international demand and obligations, including under GAVI’s Covax facility to developing countries,” the MEA added. GAVI is a global vaccine alliance.